---
title: A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients
nct_id: NCT01236820
overall_status: UNKNOWN
sponsor: China Medical University Hospital
study_type: OBSERVATIONAL
primary_condition: Cardiovascular Disease
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01236820.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01236820"
ct_last_update_post_date: 2010-11-09
last_seen_at: "2026-05-12T06:10:07.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients

**Official Title:** L5 as a Risk Factor of Cardiovascular Disease in Chronic Kidney Disease and Dialysis Patients

**NCT ID:** [NCT01236820](https://clinicaltrials.gov/study/NCT01236820)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 48
- **Lead Sponsor:** China Medical University Hospital
- **Conditions:** Cardiovascular Disease, Chronic Kidney Disease Patients, Hemodialytic Patients, High LDL Level, High L5 Level
- **Start Date:** 2010-09
- **CT.gov Last Update:** 2010-11-09

## Brief Summary

The purpose of this study is to determine whether L5, one of the Low Density Lipoproteins, is an effective predicting factor for cardiovascular disease in chronic renal and hemodialytic patients.

## Detailed Description

Cardiovascular disease (CVD) is the most important cause of death of chronic kidney disease (CKD) and hemodialysis (HD) patients. Low Density Lipoprotein (LDL) is an essential indicator of CVD.The higher the plasma LDL level, the higher the risk of CVD. LDL is a heterogenous substance composed of different mass and size. Oxidized LDL (oxLDL) is the oxidation product of LDL and is the most important component of LDL associated with CVD. The oxLDL is mostly trapped within tissue and not easily to be detected from blood. L5 iw a kind of electronegative LDL and is associated with CVD in smokers and diabetic patients, even if these patients have normal plasma LDL. Uremia patients have lipid profile different from that of general people,while HD Patients have lower LDL and CKD patients have LDL higher than that of general population. Thus LDL plasma level cannot fully explain the high risk of CVD in CKD and HD patients. As patients with normal LDL but high L5 are prone to have CVD, we suspect there might be association of L5 with CVD in both CKD and HD patients.

## Eligibility

- **Minimum age:** 20 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* clinical diagnosis of CKD
* clinical diagnosis of HD

Exclusion Criteria:

* N/A
```

## Arms

- **Normal** — Healthy population
- **CKD Patients** — Chronic Kidney Disease, in Stage III-V
- **HD patients** — End-stage renal disease patients undergoing hemodialysis

## Locations (1)

- China Medical University Hospital, Taichung, Taiwan, Taiwan — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.china medical university hospital|taichung|taiwan|taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01236820.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01236820*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*